Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

News | May 20, 2011

May 20, 2011 - Boston Scientific Corporation today announced 12-month results from its PLATINUM Small Vessel study,...

News | May 20, 2011

May 20, 2011 – e-BioMatrix post-marketing surveillance (PMS) registry information presented at EuroPCR 2011 has...

News | May 16, 2011

May 16, 2011 – In a coronary stent patent lawsuit, a jury said Cordis owes Boston Scientific approximately $19.5...

News | May 11, 2011

May 11, 2011 - Micell Technologies announced that positive preclinical data will be presented at the EuroPCR...

Feature | April 08, 2011 | Dave Fornell

April 9, 2011 - The Resolute zotarolimus-eluting stent using a new biocompatible polymer achieved a lower rate of...

Feature | April 08, 2011

In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed...

The rates of death, heart attack and stroke were equal for patients in the PRECOMBAT trial, regardless if they received a stent or CABG.

Feature | April 08, 2011 | Dave Fornell

A study from a South Korean research team found that angioplasty with a sirolimus-eluting stent was non-inferior to...

Feature | April 06, 2011

April 6, 2011 – One-year results from the pivotal PLATINUM Workhorse trial were presented at the American College of...

News | April 06, 2011

April 6, 2011 – Results from a pooled patient-level analysis favored a next-generation paclitaxel-eluting stent....

Feature | April 06, 2011

April 6, 2011 – A pooled analysis of the SPIRIT II, III, IV and COMPARE trials further reinforces the positive...

News | March 21, 2011

March 21, 2011 - OrbusNeich today announced it filed a lawsuit in the Netherlands against a doctor and...

News | February 21, 2011

February 21, 2011 – Two drug-eluting coronary stent systems have been launched in India. Boston Scientific’s Promus...

News | February 21, 2011

February 21, 2011 – The first patient has been enrolled the DESSOLVE II study to support CE mark for a coronary...

News | January 26, 2011

January 26, 2011 – Patient enrollment has begun in China for a trial evaluating the safety and effectiveness of a...

News | January 24, 2011

January 24, 2011 – Patient enrollment was completed in the EVOLVE clinical trial, which is designed to assess the...

Overlay Init